These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. DNA topoisomerase I-targeting drugs as radiation sensitizers. Chen AY; Choy H; Rothenberg ML Oncology (Williston Park); 1999 Oct; 13(10 Suppl 5):39-46. PubMed ID: 10550825 [TBL] [Abstract][Full Text] [Related]
5. [Therapeutic approach for colorectal cancer with topoisomerase as a molecular target]. Tsunoda T Nihon Rinsho; 2003 Sep; 61 Suppl 7():472-5. PubMed ID: 14574938 [No Abstract] [Full Text] [Related]
6. Topoisomerase I inhibitors. An overview of the camptothecin analogs. Burris HA; Fields SM Hematol Oncol Clin North Am; 1994 Apr; 8(2):333-55. PubMed ID: 8040144 [TBL] [Abstract][Full Text] [Related]
7. [Topoisomerases I: new targets for the treatment of cancer and mechanisms of resistance]. Pourquier P; Pommier Y Bull Cancer; 1998 Dec; Spec No():5-10. PubMed ID: 9932078 [TBL] [Abstract][Full Text] [Related]
8. Topoisomerase I poisons and suppressors as anticancer drugs. Bailly C Curr Med Chem; 2000 Jan; 7(1):39-58. PubMed ID: 10637356 [TBL] [Abstract][Full Text] [Related]
10. p53 and p21 are major cellular determinants for DNA topoisomerase I-mediated radiation sensitization in mammalian cells. Chen AY; Scruggs PB; Geng L; Rothenberg ML; Hallahan DE Ann N Y Acad Sci; 2000; 922():298-300. PubMed ID: 11193905 [No Abstract] [Full Text] [Related]
11. Topoisomerase I inhibitors: topotecan and irenotecan. Creemers GJ; Lund B; Verweij J Cancer Treat Rev; 1994 Jan; 20(1):73-96. PubMed ID: 8293429 [No Abstract] [Full Text] [Related]
12. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Pommier Y; Pourquier P; Fan Y; Strumberg D Biochim Biophys Acta; 1998 Oct; 1400(1-3):83-105. PubMed ID: 9748515 [TBL] [Abstract][Full Text] [Related]
13. Homocamptothecins: potent topoisomerase I inhibitors and promising anticancer drugs. Bailly C Crit Rev Oncol Hematol; 2003 Jan; 45(1):91-108. PubMed ID: 12482574 [TBL] [Abstract][Full Text] [Related]
14. The mechanism of topoisomerase I poisoning by a camptothecin analog. Staker BL; Hjerrild K; Feese MD; Behnke CA; Burgin AB; Stewart L Proc Natl Acad Sci U S A; 2002 Nov; 99(24):15387-92. PubMed ID: 12426403 [TBL] [Abstract][Full Text] [Related]
15. DNA topoisomerase inhibitors. Capranico G; Giaccone G; Zunino F; Garattini S; D'Incalci M Cancer Chemother Biol Response Modif; 1994; 15():67-86. PubMed ID: 7779607 [No Abstract] [Full Text] [Related]
16. Silatecan DB-67 is a novel DNA topoisomerase I-targeted radiation sensitizer. Chen AY; Shih SJ; Garriques LN; Rothenberg ML; Hsiao M; Curran DP Mol Cancer Ther; 2005 Feb; 4(2):317-24. PubMed ID: 15713902 [TBL] [Abstract][Full Text] [Related]
17. [Molecular determinants of response to topoisomerase I inhibitors]. Pourquier P; Lansiaux A Bull Cancer; 2011 Nov; 98(11):1287-98. PubMed ID: 22049384 [TBL] [Abstract][Full Text] [Related]
18. Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines. Keshelava N; Groshen S; Reynolds CP Cancer Chemother Pharmacol; 2000; 45(1):1-8. PubMed ID: 10647494 [TBL] [Abstract][Full Text] [Related]
19. Structure-based analysis of the effects of camptothecin on the activities of human topoisomerase I. Champoux JJ Ann N Y Acad Sci; 2000; 922():56-64. PubMed ID: 11193925 [TBL] [Abstract][Full Text] [Related]
20. Platinated DNA adducts enhance poisoning of DNA topoisomerase I by camptothecin. van Waardenburg RC; de Jong LA; van Eijndhoven MA; Verseyden C; Pluim D; Jansen LE; Bjornsti MA; Schellens JH J Biol Chem; 2004 Dec; 279(52):54502-9. PubMed ID: 15471886 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]